CANDEL THERAPEUTICS, INC. Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
CANDEL THERAPEUTICS, INC. (CADL) had Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount of $22.30 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions · last filed 2026-08-13
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $22.30M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $21.30M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $11.20M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $12.30M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount as first filed |
|---|---|---|
| 2026-06-30 | $22.30M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $21.30M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $11.20M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $12.30M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $13.00M 10-Q · filed 2025-08-14 | |
| 2024-12-31 | $1.90M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $12.70M 10-Q · filed 2025-05-13 | $2.80M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $3.90M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $4.40M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $6.10M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $5.50M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $6.50M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $6.20M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $7.60M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $7.90M 10-Q · filed 2023-11-09 | $7.95M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $7.30M 10-Q · filed 2023-08-10 | $7.33M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $7.50M 10-Q · filed 2023-05-11 | $7.54M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $6.30M 10-K · filed 2023-03-30 | $6.30M 10-K · filed 2022-03-29 |
| 2021-09-30 | $6.28M 10-Q · filed 2022-11-10 | $5.93M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $6.06M 10-Q · filed 2022-08-05 | |
| 2021-03-31 | $5.42M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $4.78M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |